Search academic texts

Information × Registration Number 0217U000442, 0116U003575 , R & D reports Title Role of molecular genetic of somatic cells, pharmacological and chemical characteristics of ABO antigens and medicinal drugs in selection of individualized therapy programs in patients with chronic lymphoproliferative neoplasms popup.stage_title Head Minchenko Zhanna; Liubarets Tatiana, Registration Date 03-02-2017 Organization State institution "National research centеr for radiation medicine of the National academy of medical sciences of Ukraine " popup.description2 Objective: to create groups of priority monitoring for estimation of clinical course of disease and effectiveness of modern chemotherapy regimes taking into consideration pharmacological and chemical characteristics of ABO genes after analyzing the results of retrospective and prospective clinical and hematological investigations in chronic lymphoproliferative neoplasms (ChLPN), and molecular and cytogenetic characteristics of substrate cells. Clinical and hematological features of 98 ChLPN patients (irradiated and non-irradiated) treated at the Department of the Oncohematоlogy of ICR of NRCRM in 2014-2016 years taking into consideration disease stage, clinical peculiarities and effectiveness of treatment regimes using monoclonal anti-CD20 antibody (Rituximab) in CLL cases (61 patients) and proteasome inhibitor (Bortesomib) in MM cases (37 patients) were analyzed. Such complications as autoimmune hemolytic anemia and bulky disease in CLL III-IV stage persons suffered after the ChNPP accident (main group) revealed more frequently, Richter transformation was diagnosed in one CLL III stage patient. In MM patients М-protein was predominantly identified as Ig А and kappa-chains, more rarely as Ig G and lambda-chains, Bence-Jones myeloma in patients of main group and comparison group (non-irradiated persons) was diagnosed with the same frequency. Association of abnormalities of chromosome 13 (del13q34) with translocation t(4;14), and translocation t(14;16) with abnormalities of chromosome 16 was revealed in primary refractory disease or in MM patients with minimal therapy effectiveness and disease complications (Ro Spirman=0,33; p<0,05). When ABO phenotypes were analyzed increasing of B group antigens distribution rate in association with gene balance in MM patients not in remission were shown. The increasing of serum interleukin concentration (IL-6, TNF-alpha) in MM patients newly diagnosed was revealed comparing with control group (3,6 and 3,2 times, respectively). In the most of MM patients (90 %) effectiveness of chemotherapy was associated with reducing of IL-6 and TNF-alpha (1,7 and 1,5 times, respectively). Groups of priority monitoring for future investigation were formed after analysis of retrospective and prospective ChLPN cases taking into consideration clinical and hematological features of disease, molecular and cytogenetic, immunogenetic, and pharmacological and chemical characteristics of ABO genes in CLL and MM patients. Product Description popup.authors Балан Валентина Володимирівна Бебешко Володимир Григорович Дмитренко Олена Олександрівна Мішаріна Жанна Анатоліївна Сілаєв Юрій Олегович Сітько Валентина Віталіївна Товстоган Анжела Олександрівна Хоменко Віктор Іванович Шляхтиченко Тетяна Юріївна popup.nrat_date 2020-04-02 Close